The UK Competition and Markets Authority or CMA has approved AstraZeneca Plc.'s (AZN.L, AZN) proposed acquisition of Alexion Pharmaceuticals Inc. (ALXN). The acquisition is expected to close on 21 July 2021.
AstraZeneca noted that a group focusing on rare diseases will be created. The group will be named 'Alexion, AstraZeneca Rare Disease', and will be headquartered in Boston, US.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com